Please use this identifier to cite or link to this item: https://scholarhub.balamand.edu.lb/handle/uob/67
DC FieldValueLanguage
dc.contributor.authorJourdi, Hussamen_US
dc.date.accessioned2020-12-23T08:24:56Z-
dc.date.available2020-12-23T08:24:56Z-
dc.date.issued2015-
dc.identifier.urihttps://scholarhub.balamand.edu.lb/handle/uob/67-
dc.description.abstractCalpains refer to a family of intracellular non-lysosomal cysteine proteases. They are regulatory rather than digestive proteases because of limited substrate proteolysis. Activation of calpains at neutral pH distinguishes them from other cysteine proteases such as cathepsins. Most calpains have widespread distribution in various tissues of the body. The best-characterized isoforms μ-calpain and m-calpain are the predominant calpains in the central nervous system (CNS). At least in vitro, μ-calpain and m-calpain (a.k.a. calpain-1 and calpain-2) are activated by μM and nearly mM Ca2+ concentrations, respectively. Considering their numerous important functions in the CNS, identifying plausible biomarkers for calpain activation represents a major advancement for the diagnosis and treatment of brain diseases and for better understanding of their individual physiological roles. This is a challenging and complicated task as μ-calpain and m-calpain have overlapping substrate specificity and because the presence of substrate degradation products cannot distinguish between activation of these two calpains. Moreover, although substrate degradation products have been used as indicators (biomarkers) of calpain activation, it has been difficult to discriminate between those degraded by physiological or pathological processes that involve either one of the two isoforms. Further, the limited substrate cleavage under physiological conditions coupled to little prevalence of degradation products renders their detection more challenging. Indeed, aside from possible quantitative differences in the magnitude of degradation of any single substrate, it remains to be determined whether any specific degradation product can be used as a biomarker to point out physiological substrate cleavage and tell it apart from pathological degradation. In light of exciting new studies revealing phosphorylation-dependent activation of calpains published in the past few years this chapter reviews the patho.en_US
dc.format.extent64 p.en_US
dc.language.isoengen_US
dc.titleBiomarkers for differential calpain activation in healthy and diseased brains: a systematic reviewen_US
dc.typeBook Chapteren_US
dc.contributor.affiliationDepartment of Biologyen_US
dc.description.startpage154en_US
dc.description.endpage219en_US
dc.date.catalogued2019-05-03-
dc.description.statusPublisheden_US
dc.identifier.OlibID191598-
dc.identifier.openURLhttps://scholar.google.com/scholar?oi=bibs&cluster=3132951586182687393&btnI=1en_US
dc.relation.ispartoftextK. Wang, Z. Zhang & F. Kobeissy (Eds.), Biomarkers of brain injury and neurological disorders.CRC Press.en_US
dc.provenance.recordsourceOliben_US
crisitem.author.parentorgFaculty of Arts and Sciences-
Appears in Collections:Department of Biology
Show simple item record

Record view(s)

29
checked on Apr 25, 2024

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.